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Tests detecting biomarkers for screening of colorectal
cancer: What is on the horizon?
Abstract
Aim: To identify new and emerging screening tests for colorectal cancer
(CRC) that involves detection of various biomarkers like blood, DNA and
RNA in samples of faeces, tissue or blood.
Angaja Phalguni1
Helen Seaman2
Kristina Routh1Current practice: Screening for CRC can be done by bowel visualisation
techniques and tests that measure biomarkers. The Bowel Cancer Stephen Halloran2
Screening Programme (BCSP) in England uses a guaiac faecal occult
blood test.
Sue Simpson1
Methods: The strategy was to search available literature, identify de-
velopers and contact them for relevant information. Advice from experts 1 NIHR Horizon Scanning
Research & Intelligencewas sought on potential utility and likely impact of identified technologies
on the BCSP. Centre, School of Health and
Population Sciences,Results:Ninety-three companies and five research groups were contact-
ed. Sixty-nine relevant tests were identified. Detailed information was University of Birmingham,United Kingdom
available for 48 tests, of these 73%were CEmarked and the remainder
2 University of Surrey, NHS
Bowel Cancer Screening
were considered as emerging. Forty-nine tests use immunochemical
methods to detect occult blood in faeces. Eight, four and two tests detect
Southern Programme Hub,
United Kingdom
biomarkers in a sample of blood, or exfoliated cells either shed in faeces
or collected from rectal mucosa respectively. Six tests were grouped as
‘other tests’. Most of the identified tests are performed manually and
give qualitative detection of biomarkers.
Conclusion: Variation in test performance and characteristics was ob-
served amongst the 69 identified tests. Automated, quantitative FIT
with a variable cut off are the preferred approach in the BSCP. However
the units used to report FITs results do not enable comparison across
products. Tests detecting biomarkers other than occult blood are more
specific to neoplasms but have limited sensitivity due to the heterogen-
eity of cancer. Research is ongoing to identify an optimal panel of bio-
markers, simplifying and automating the test, and reducing the cost.
Keywords: colorectal cancer, colorectal carcinoma, colorectal tumors,
colorectal neoplasms, screening, early detection, cancer screening,
cancer screening tests, early diagnosis of cancer
Introduction
Colorectal cancer (CRC) is the thirdmost common cancer
and the second leading cause of cancer death in the UK
[1]. The majority of CRCs develop from small benign ad-
enomatous polyps lining the bowel wall [2]. Progression
of an adenoma into cancer takes approximately 10 years
[3]. The twomainmethods of screening for CRC are bowel
visualisation and measurement of faecal biomarkers
(Figure 1) [4].
Faecal occult blood tests (FOBT) are currently the most
widely used screening test for CRC, based on the fact
that asymptomatic colorectal neoplasia may bleed. The
two main types of FOBT are guaiac FOBTs (gFOBt) and
faecal immunochemical tests for haemoglobin (FIT). The
gFOBt detects the pseudoperoxidase activity of the haem
component of haemoglobin, whilst FIT detect the pres-
ence of globin by immunochemical reactions [5]. Other
screening tests use assays that detect DNA, RNA and
protein in samples of faeces, tumour tissue and blood
[6], [7], [8]. These assays target single or multiple cancer-
related mutations that result from disturbances of
biological processes in the intestinal epithelial cells.
There is no single internationally agreed CRC screening
method. Most screening programmes apply a two-step
approach, which includes a non-invasive test (gFOBt or
FIT) followed by a bowel visualisation technique (colonos-
copy or sigmoidoscopy) for test-positive individuals, while
others use colonoscopy or sigmoidoscopy as the primary
screening tool. The Bowel Cancer Screening Programme
(BCSP) in England offers biennial CRC screening to indi-
viduals aged 60–74 using a gFOBt followed by colonos-
copy for test-positive individuals [9].
There is good evidence from four large randomised-con-
trolled trials that gFOBt in population-based screening
can reduce CRC mortality [10]. The gFOBt has several
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Figure 1: Flowchart to illustrate the various methods used for screening for CRC
advantages over FIT including lower cost, good sample
stability and a card-based sample collection system that
enables simple and cheap mailing arrangements, al-
though its limitations include no automated analysis, no
facility to adjust the cut-off concentration for positivity,
poorer participant compliance than FIT [8], [11], [12],
potential interference from upper gastrointestinal (GI)
bleeding, [13] and low sensitivity and specificity for ad-
enomas and early stage CRC [11], [14]. In addition, gFOBt
are susceptible to dietary interference from red meat
(haem is not specifies-specific), vegetable peroxidases
(false-positives) and antioxidants such as Vitamin C (false-
negatives). Crude modification to the guaiac test using
rehydration before analysis can increase analytical
sensitivity but this makes the test more sensitive to inter-
ference from diet and unsuitable for population screening
[15].
FIT are specific for human haemoglobin and so eliminate
the potential for dietary interference [16]. FIT are also
more specific for lower GI bleeding because globin is likely
to have been degraded in faeces if it originated in the
upper GI tract [16]. The superiority of FIT over gFOBts is
now widely recognised and the European Quality Assur-
ance Guideline on CRC Screening published in 2011 re-
commends FIT in preference to gFOBT [5], [8], [17].
Various countries have adopted FIT into their CRC
screening programmes and the BCSP plans to replace
gFOBt with FIT [18].
Aim
The aim of this horizon scanning review was to provide
a summary of new and emerging tests that detect bio-
markers with potential for use in CRC screening.
Method
A horizon scanning review attempts to identify and
present early information on all new and emerging tech-
nologies relevant to the topic area of interest. In this re-
view the area of interest was tests that detect blood or
other biomarkers in samples of faeces, blood or tissue
which had potential use for CRC screening. To ensure
relevant technologies were captured, tests were included
if they were emerging i.e. not yet available for use within
the health care system but in development and expected
to be CE-marked or launched within the next 2 years; or
new i.e. tests that had been available for use in the UK
for ≤5 years but may not have yet been considered for
use, or were in the early phases of adoption.
Between October 2011 and March 2012, potential tests
were identified using recognised horizon scanning meth-
ods [19]. These included a combination of internet
searches, expert suggestions and direct contact with
companies (Table 1). For technologies in development
or in the early phases of adoption, it is common for there
to be a lack of publicly accessible information and scientif-
ic data available. This is particularly true for non-pharma-
ceutical technologies such as diagnostic tests. Therefore
further information about the initial long-list of individual
tests identified was requested from developers. This in-
volved contacting companies or research institutions
directly using a standard proforma developed by the NIHR
Horizon Scanning Research & Intelligence Centre (HSRIC).
Information requested included test description (e.g.
name, synonyms, intended indication; test method; bio-
markers detected etc.); details on the usability of the test
(e.g. details of specimen collection, dietary restrictions,
transportation requirements etc.); the test process, ana-
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Table 1: Steps involved in conducting the horizon scanning review
lysis and interpretation of results; stage of development;
cost and data on test accuracy. If no contact with the
company could be established, a focused internet search
was carried out for individual technologies to obtain any
information available.
When information had been collated for the initial list of
potential screening tests, they were categorised as either
‘emerging’ or ‘new’ based on their development time-
frame. Tests that were found to be established were ex-
cluded from the final list. An expert advisory group
(Table 1) were sent the final list and invited to provide
informed opinion on the potential utility, advantages
and/or disadvantages of tests. The resulting output was
a descriptive list of new and emerging tests detecting
biomarkers that have potential for use in CRC screening.
No analysis of evidence data obtained during the identi-
fication stages was carried out. The descriptive list can
be used by those commissioning and planning further
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Figure 2: Flowchart to illustrate key findings of the review
research (both primary and secondary), policymakers (in
this case national screening committees), health care
funders and health care practitioners.
Results
We identified 145 tests involving detection of biomarkers
that had potential for use in CRC screening; these were
provided by 93 companies and five academic research
groups. Sixty-one (62%) of the companies were able to
provide the information requested and 69 (48%) tests
met the review inclusion criteria. The remaining 76 tests
(52%) were excluded, because they did not meet the in-
clusion criteria for a new or emerging test, or the test was
a duplicate of another that had been identified. We ob-
tained details on the development status of 48 tests.
Fifteen tests (31%) were CE marked and available for
clinical use in the NHS, eight (17%) were CE marked but
not yet available for clinical use in the NHS, 12 (25%)
were CE marked but information regarding clinical use
in the NHS was not available, and 13 (27%) were con-
sidered as emerging.
Figure 2 summarises the 69 tests included in the review
and lists the analytical methods used to detect and
measure the biomarkers. Themajority of tests (49; 71%),
including four emerging tests, use an immunochemical
method to detect blood in faeces. Eight (11.6%), including
six emerging tests, detect other biomarkers in blood; four
(5.8%) detect biomarkers in exfoliated cells shed in the
faeces, and two (2.9%) emerging tests use exfoliated
cells collected directly from the rectal mucosa. Six (8.7%)
tests, including one emerging test, were grouped as
‘other tests’ (as the test method used and/or the sub-
stance detected by these tests did not allow for them to
be grouped under the test categories mentioned above).
Only eight of the 13 tests considered as ‘emerging’ could
be considered as innovative, using a novel method or
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detecting biomarkers different from existing marketed
tests. Of these, five tests (products 56, 57, 58, 59 and
60) detected biomarkers such as methylated septin 9, a
panel of DNA biomarkers, antibodies against p53 proteins
or circulating tumour cells in a sample of blood; two tests
(products 61 and 62) use exfoliated cells collected directly
from rectal mucosa tomeasure the concentration of DNA
or analyse the alterations in the nanoscale architecture
of colonocytes by using a partial wave spectroscopic mi-
croscopy instrument; and one test (product 65) detects
the amount of cancer-associated carbohydrate in rectal
mucus.
Table 2 provides details of the tests identified (confiden-
tial data prevented inclusion of one FIT test). Themajority
of FIT (94%) identify blood in faeces by detecting globin,
some (6%) detect haemo/haptoglobin complexes. Three
tests (products 8, 26 and 45) detect globin and other
proteins such as transferrin or ferritin. Based on available
information on 45 FIT, 30 (67%) use immunochromatog-
raphy (enzyme immunoassay in lateral flow systems) to
detect blood in faeces (qualitative devices). Other immuno-
chemical testmethods include colloidal gold agglutination
(n=1), reverse passive haem-agglutination (n=1), magnet-
ic particle agglutination (n=1), immunoturbidimetry (n=6),
and enzyme immunoassay/ELISA (n=6). Eleven FIT (22%)
provide a quantitative measurement of faecal human
haemoglobin concentration and analysis can be auto-
mated. Thirty-three FIT (67%) provide qualitative detection
of human haemoglobin, of which only two can be auto-
mated (products 22 and 27); the others require visual
interpretation of test results.
The main method of specimen collection for tests that
detect biomarkers in faeces involves collection of a single
faecal sample into liquid buffer contained in specialised
collection tubes. Only three FIT (products 13, 21 and 44)
devices use dry cards for collection of the faecal speci-
men. None of the tests included the need for any dietary
restrictions. The cost of tests that detect blood in faeces
is generally considerably lower than tests that detect
other biomarkers in samples of faeces, exfoliated cells
or blood.
Information on cut-off concentrations (for FIT), sample
stability and clinical sensitivity and specificity of the tests
for CRC or adenomas was available for some tests.
However, the importance of consistency in the way this
information is reported has only recently been recognised
[20], [21] which can make simple comparison across
products both inaccurate and misleading.
Discussion
A large number of potential markers for CRC screening
was identified, themajority of which are already available
for clinical use in the UK and relatively few of which use
a novel approach.Most new and emerging identified tests
were FIT. The 49 FIT that were identified varied in their
reported test performance (clinical sensitivity and spe-
cificity for CRC and adenomas) and test characteristics
(substance detected, test method, method of sample
collection, cut-off and type of detection).
A non-invasive, inexpensive, clinically validated test that
is acceptable to users and facilitates automated high-
throughput testing would be ideal for a population-based
screening programme. FIT are superior to gFOBts as a
screening test for CRC, primarily because of greater
clinical sensitivity, specificity and screening compliance
[11], [14]. Improved compliance may be due to the need
for a single sample and an easier stool collectionmethod.
The use of a liquid buffer to help preserve haemoglobin
in FIT presents difficulties and expense for safely mailing
the test kits to and from subjects [22]. Whilst new buffers
are appearing on themarket, the stability of haemoglobin
in FIT sample collection tubes is generally poorer than
that of haemoglobin applied to a gFOBt [23].
Several factors might influence the stability of haemo-
globin in a buffer solution including temperature [24] and
sample return time [25]. To slow down the degradation
of haemoglobin, in most new and emerging FIT, the
sample is added to a preservative buffer and the advice
is to store at temperatures lower than room temperature.
Information on sample stability was received from some
companies, but as the definition of stability has not yet
been standardised it makes company claims difficult to
compare.
Both qualitative and quantitative FIT were identified.
Qualitative tests are not appropriate for a large screening
programme since the concentration at which tests be-
come positive is set by the manufacturer and demand
for colonoscopy is effectively set by the manufacturer
[23]. Qualitative tests, which use laminar flow immuno-
chromatography, require subjective visual assessment
of results and make quality assurance difficult. Consist-
ency in interpretation of test results could be improved
by designating a centralised location for analysis of all
tests or by using tests with automated reading [26].
Analysis of only two of the qualitative FIT identified
(products 22 and 27) can be automated.
Quantitative FIT generally use automated analysis to de-
termine the faecal haemoglobin concentration, which al-
lows high throughput testing, improves reproducibility
and removes inter-observer variation in interpretation of
test results [5]. A further benefit of quantitative FIT is that
the cut-off concentration can be adjusted according to
colonoscopy capacity and the intended detection rate in
the screened population [4]. Since the amount of faecal
haemoglobin is likely to be higher in patients with CRC
than in patients with advanced adenomas, a difference
in the cut-off will affect primarily the detection of ad-
vanced adenomas [14], [27], [28], [29], [30]. The rela-
tionship between the concentration of haemoglobin in
faeces and the risk of cancer or advanced adenoma has
yet to be fully exploited with quantitative tests. These
tests will enable more effective screening algorithms to
be derived which combine haemoglobin concentration
with other parameters such as screening history, recent
endoscopy, and the age and sex of the subject [31].
Current FIT measure the concentration of haemoglobin
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Table 2: Characteristics of tests for screening of CRC included in the study
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in the buffer (e.g. ng haemoglobin/mL of buffer solution).
The numeric cut-off concentration, if quoted in mass of
haemoglobin in a device buffer, will be directly related to
the design of a FIT, the volume of the buffer solution it
holds and the mass of sample it collects [20], [21]. The
cut-off is therefore unhelpful when comparing perform-
ance of one FIT with another. To perform such compari-
sons it is recommended that FIT results be reported as
concentration of haemoglobin in the faecal sample (µg
haemoglobin/g faeces) [20], [21].
Both gFOBts and FIT require faecal sampling and this is
likely to be a barrier to high compliance [32]. Three tests
(one FIT [product 21] and two ‘other tests’ [products 63
and 66]) use methods that minimise or eliminate the
need for faecal handling; the FIT uses a long-handled
brush collection system and the others use a test tissue
that is dropped into the toilet bowl after a bowel move-
ment. However, both these products are vulnerable to
potential interference from disinfectants and other
cleaning products added to toilet water.
To be able to choose the most clinically-effective FIT
testing system, it is essential that results from different
systems can be compared and that critical steps in the
analytical and reporting process are standardised. FIT
currently use different analytical materials, report results
unique to the individual device and have no consensus
method of measuring and reporting sample collection
mass or test stability. To aid the difficult process of select-
ing a test kit and cut-off concentration appropriate to in-
dividual screening programmes the World Endoscopy
Organization formed an Expert Working Group ‘FIT for
Screening’ in 2011 to identify and promote standardisa-
tion of FIT [16], [20], [21], [33], [34], [35].
The clinical performance of gFOBts and FIT is affected by
lesions that bleed intermittently (sensitivity) and by non-
specific bleeding from lesions other than CRC and ad-
enomas (specificity). Fifteen new and emerging tests that
detect biomarkers other than blood in faeces were iden-
tified. Like FIT, these varied in test performance and
characteristics, although unlike FIT, the biomarkers de-
tected by these tests will be more consistently present
and are more specific to neoplasms [36]. Nevertheless,
the decision to use them in screening might bring addi-
tional difficulties. Tests that detect biomarkers in exfoli-
ated cells shed in faeces still require faecal handling and
that is linked with poor compliance and poor quality of
biomarker due to faecal contamination could decrease
test sensitivity. Also, human DNA accounts for roughly
0.01% of faecal DNA and the remaining DNA is either
from microflora or diet [37]. The stability and isolation
procedures of human DNA from stool are affected by the
abundance of bacteria and cytolytic substances in the
faeces [38]. Quality of biomarker from the faeces can be
improved with a new purification method to extract high
quality biomarkers from a larger faecal sample than that
used for gFOBt or FIT [39]. Screening tests that use exfoli-
ated cells collected directly from rectal mucosa are un-
likely to prove feasible for a screening programme be-
cause of the resource cost (e.g. healthcare staff time)
associated with performing a digital rectal examination
to collect the sample. In addition, the invasive nature of
this procedure and the need to attend a clinic appoint-
ment are likely to be deterrents.
A number of new and emerging tests detecting biomark-
ers in blood were identified that may have benefits over
stool testing. Firstly, there are few microflora that can
decrease the quality of the biomarker [40] and secondly
a test in bloodmight improve screening compliance since
a single blood test might prove more convenient and ac-
ceptable to the screening participants [40]. If a blood
sample is being taken for other clinical reasons, perhaps
as a general ‘wellness assessment’, this might prove at-
tractive, particularly in countries that have well-developed
disease prevention programmes. A blood sample carries
associated healthcare costs and might be more relevant
to the proportion of screening population that is unwilling
or unable to collect faecal samples.
Biomarkers such as methylated DNA are present in very
small amounts in blood whichmakes them less attractive
for detection of early stage cancers and adenomas [6].
No single biomarker has yet yielded perfect sensitivity to
CRC and advanced adenomas due to the heterogeneity
of the tumours [37]. Use of a panel of biomarkers will in-
crease sensitivity while potentially maintaining specificity
[7]. Three tests (products 54, 56 and 60) identified in
this study detect a panel of biomarkers but this further
increases the complexity and the cost of the test. Lack
of large scale population-based validation studies and
the uncertainty about the frequency of administration of
these tests has further limited their clinical utility [37],
[41]. Since the review was conducted, US investigators
have reported on the performance of FIT versus a panel
of stool DNAmarkers for CRC plus FIT and concluded that
the panel of CRC markers showed higher single-applica-
tion sensitivity than FIT alone for both CRC and advanced
precancerous lesions (including sessile serrated ad-
enomas), although with lower specificity [7]. The panel
test requires a complete stool sample, which introduces
extra cost and impracticality to an already expensive
testing procedure. Research will continue to identify either
a sensitive single biomarker or a panel of biomarkers that
simplify and automate the testing and do so at an afford-
able cost [8].
Study limitations
Themajority of the tests identified were either developed
by, or have the support of, a major in vitro diagnostic
manufacturer; some of the more sensitive information
was frequently regarded as ‘commercial in confidence’.
The nature of the in vitro diagnostic industry has also
presented a number of challenges since tests are often
developed by individuals, universities, or small start-up
companies and then acquired, or merged with, larger
companies as the commercial opportunities are realised.
This process is confounded by product and company
names changes which may account for the lack of re-
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sponse to our requests for information from some com-
panies.
The methods used to identify technologies and obtain
further information about those technologies can mean
that the data obtained is not always current, can be ac-
curate or can be subject to bias. These limitations are
minimised by using a variety of identification sources and
involving subject experts.
Identification of the tests took place during October 2011
to March 2012 resulting in some of the information
presented being out of date. The nature of horizon scan-
ning is that information identified on technologies that
are in development is continually changing. However, the
information presented provides a snap-shot of this rapidly
changing field. The importance of this information being
to alert policy makers, commissioners, research funders
and evaluators to the developments in this field and to
raise awareness of the range and complexities of the
emerging tests. This information feeds into planning and
is not generally available elsewhere other than through
expensive market reports.
Conclusion
There is a recognised need for a screening test for
colorectal cancer that is non-invasive, inexpensive and
acceptable. The test should have sufficient clinical
sensitivity to produce cost effective reductions in the in-
cidence and mortality of CRC, and a clinical specificity to
minimise unnecessary colonoscopies, patient anxiety and
cost to the health care system. FIT were themost common
new screening tests identified in this study which indi-
cates a renewed interest in faecal blood testing and the
potential for further product enhancement. Automated
quantitative FIT with a variable cut-off are currently the
preferred test for CRC screening programmes but a test
reliant upon the detection of blood in faeces has inherent
limitations. Advanced adenomas and early cancers should
be the target lesions of a screening programmedesigned
to reduce both incidence and mortality of CRC. These
early lesions may bleed lightly and intermittently, if not
at all, and will therefore elude FIT detection. The holy grail
is a highly sensitive test that is specific for CRC. Emerging
tests use biomarkers other than blood, for example DNA
and specific proteins both in blood and in faeces, or a
panel of biomarkers with FIT. To facilitate the decision
on the adoption of various tests identified in this review,
and to ensure the NHS secures the most cost and clinic-
ally-effective testing approach, it is essential that data
on the clinical validation of new and emerging tests in
the screening population is made available.
The search for a better test for CRC continues and whilst
new products appear on the market, they will have to
demonstrate that they are both more clinically effective
and affordable for population-based screening.
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